



# NeuroBlot™

## A Personalized Memory Test Determining Risk of Cognitive Decline


[www.NeuroBlot.com](http://www.NeuroBlot.com)

### OVERVIEW

Approximately 50 million people live with dementia worldwide, and this number is expected to increase to 130 million by 2050. Diagnosis is typically made in the late stages of disease, and therefore a diagnostic test which could detect early onset of cognitive decline is urgently needed.

### SOLUTION

XVIVOS Biosciences Inc. has developed a patent-pending personalized digital memory test ([NeuroBlot](#)) which aims to replace the current standard of pen-and-paper memory tests that are delivered as a first-line diagnostic tool for detecting dementia. **NeuroBlot** leverages user content from social media to generate an individualized examination, with the goal of anticipating the user's risk of cognitive decline. This unique cognitive assessment generates actionable insights for primary care providers, and could reduce the long-term financial burden on the healthcare system by identifying at-risk individual's prior to late stages of disease.



### COMPETITION

several companies offer digital versions of the generic pen-and-paper-based tests, however, **NeuroBlot's** competitive advantage is that it provides PERSONALIZATION, generating questions and memory tasks based on the individual's own content (via social media) and thus knowledge. **NeuroBlot** also takes advantage of hardware features of devices (e.g. camera, microphone, accelerometer) to assess parameters of cognition.

### TEAM

We have worked together for >10 years (University of Toronto, Hospital for Sick Children), and during this time we have had many achievements, including the generation of high-quality research data as well as publishing our work in top-tier international journals (>40 peer-reviewed [publications](#) combined), two patent applications filed, and securing >\$500,000 in scholarships and research grants.

### COMPANY HIGHLIGHTS

- Personalized Neurotechnology
- Founded in Toronto, 2016
- 6 team members
- (4 PhDs, 1 MD, 1 EMBA\*)

### CONTACT

Dr. Saumel Ahmadi, CEO  
[contact@neuroblot.com](mailto:contact@neuroblot.com)

[NeuroBlot.com](http://NeuroBlot.com)



252-100 College St.  
Banting Institute  
Toronto, Canada